EQT to Buy Qiagen for 10.8 Billion
Swedish private equity firm EQT has agreed to acquire molecular testing company Qiagen for about 10.8 billion dollars. The transaction represents an 8.6 percent premium and is expected to close in mid-2027.
Xurve View
Insights:
Xurve View
Sweden-based EQT AB will acquire QIAGEN N.V. for €9.6 billion ($10.78 billion), ending years of takeover speculation for the Netherlands molecular testing firm. The buyout values Qiagen at $12.1 billion including $1.1 billion in net debt, offering €46.50 per share. The transaction reflects growing private-equity appetite as demand for molecular testing technologies accelerates.
